Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COCOS: Cediranib and Olaparib in Recurrent Ovarian Cancer
NCT02502266Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of cediranib and olaparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (7 arms), sponsored by National Cancer Institute. Primary endpoints: Progression-free Survival up to 42 months and Overall Survival up to 5 years. Started May 2016; status: active, not recruiting.
02
Drugs
cediranibolaparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02502266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02502266.